A recently published report[7] and in our own independent work have demonstrated elevated levels of NETosis markers, such as eDNA, MPO and NE.[10, 37, 38] These are characteristic features of critically ill patients with COVID‐19.[39] Hence, we hypothesized that DNase‐I could be used to ameliorate the dissolution of the main constituent of NET structure, DNA, and thus prevent NET‐related pathogenesis, including progression toward ARDS and sepsis in severe COVID‐19 patients. This evidence concerns the gene MPO and acute respiratory distress syndrome.